VBI VACCINES INC. (TSE:VBV) Files An 8-K Other Events
Item 8.01 Other Events.
On April 9, 2019, VBI Vaccines Inc. announced that its abstract related to the prophylactic hepatitis B vaccine, Sci-B-Vac®, has been selected for a late-breaking poster presentation at The International Liver CongressTM (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL) to be held in Vienna, Austria, April 10-14, 2019. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated April 9, 2019 |
VBI Vaccines Inc/BC Exhibit
EX-99.1 2 ex99-1.htm VBI Vaccines Announces Late-Breaking Poster Presentation at EASL 2019 ● Poster presentation to highlight data from three previously-conducted clinical studies of Sci-B-Vac®,…
To view the full exhibit click here
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).
